The purpose of this study was to elucidate the effect of decreased muscle mass on the toxicity and survival of patients with colon cancer treated with adjuvant chemotherapy after surgery.
READ FULL ARTICLE
From Mdlinx
Decreased muscle mass is associated with an increased risk of grade 3/4 toxicity and poorer prognosis in patients with stage 3 colon cancer, according to a recent study published in Supportive Care in Cancer.
Korean researchers led by Hee-Won Jung, MD, at the Seoul National University College of Medicine examined data on 229 patients with stage 3 colon cancer who received adjuvant oxaliplatin, 5-fluorouracil, and leucovorin chemotherapy from 2003 to 2010, measuring for effects of muscle mass on toxicity and survival. Median age was 61 years and 134 patients were male.
The researchers found that decrease in muscle mass was associated with increased toxicity in all grade 3/4 cancers in univariate and multivariate analyses.
In multivariate analysis alone, they found that an incremental decrease in muscle mass index increased the hazard of overall mortality.
The effect was further confirmed in subgroup analyses and it was further pronounced in patients who were older and obese.
The purpose of this study was to elucidate the effect of decreased muscle mass on the toxicity and survival of patients with colon cancer treated with adjuvant chemotherapy after surgery.
READ FULL ARTICLE
From Mdlinx
You’ve read {{metering-count}} of {{metering-total}} articles this month.
We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.
{{login-button}} {{register-button}}
Want to view more content from Cancer Therapy Advisor?
Register now at no charge to access unlimited clinical news, full-length features, case studies, conference coverage, and more.
{{login-button}} {{register-button}}
Please login or register first to view this content.